ACADHealthcare · BiotechnologyThe 21 Wall Street analysts covering ACADIA Pharmaceuticals, Inc. hold a median 12-month price target of $36 — +21.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores ACADIA Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ACAD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +21.4% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | UBS | Maintains | Buy | $45 → $49 |
| 12 Aug 2026 | Needham | Maintains | Buy | $38 → $41 |
| 10 Aug 2026 | Citigroup | Maintains | Buy | $35 → $39 |
| 5 Aug 2026 | Citizens | Maintains | Market Outperform | $35 → $36 |
| 5 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 5 Aug 2026 | Oppenheimer | Maintains | Perform | — |
| 5 Aug 2026 | Oppenheimer | Maintains | Perform | $23 → $25 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | $36 → $37 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 21 July 2026 | BMO Capital | Maintains | Outperform | — |
| 21 July 2026 | BMO Capital | Maintains | Outperform | $34 → $36 |
| 21 July 2026 | Stifel | Maintains | Hold | — |
| 21 July 2026 | Stifel | Maintains | Hold | $24 → $25 |
| 7 July 2026 | RBC Capital | Maintains | Outperform | — |
| 7 July 2026 | RBC Capital | Maintains | Outperform | $29 → $36 |
| 30 June 2026 | B of A Securities | Maintains | Buy | — |
| 30 June 2026 | B of A Securities | Maintains | Buy | $29 → $30 |
| 29 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 29 June 2026 | Citigroup | Maintains | Buy | — |
| 8 May 2026 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACAD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, ACADIA Pharmaceuticals, Inc. returned +15.2% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 51% of US stocks
Cheaper than 29% of US stocks
Cheaper than 28% of US stocks
Cheaper than 6% of US stocks
Higher than 65% of US stocks
Higher than 57% of US stocks
Higher than 97% of US stocks
Higher than 68% of US stocks
Higher than 92% of US stocks
Higher than 90% of US stocks
Higher than 69% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ACADIA Pharmaceuticals, Inc. has a market value of $5.1B and an enterprise value of $4.2B.
Revenue in the twelve months to 30 June 2026: $1.1B. The latest quarter grew 16.4% year on year.
Net income over the same four quarters: $380.5M, a 33.4% net margin.
Diluted earnings per share, trailing twelve months: $2.22.
Free cash flow in the twelve months to 30 June 2026: $145.6M.
Trailing P/E: 13.2×; forward P/E: 33.2× — the forward figure prices analyst consensus estimates, not reported earnings.
ACADIA Pharmaceuticals, Inc. employs 796 people — $1.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ACADIA Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The European Commission approved Acadia Pharmaceuticals' Daybu, marking the first and only treatment approved in the EU for Rett syndrome. The approval expands Acadia's geographical reach for this therapy.
Why it matters — An ACAD watcher would care because EC approval widens the company's market footprint and adds a new approved indication in Europe for its Daybu treatment.
The European Commission has granted marketing authorization to Acadia Pharmaceuticals' DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. This makes DAYBU the first and only treatment approved for Rett syndrome in the European Union.
Why it matters — The EU approval expands the commercial availability of Acadia's DAYBU beyond existing markets and establishes it as the sole approved treatment for Rett syndrome in the region, broadening its potential patient reach.
ACADIA Pharmaceuticals discussed commercial expansion plans for its marketed therapies DAYBUE and NUPLAZID during a Canaccord Genuity-hosted discussion. The company also highlighted upcoming clinical data for remlifanserin in Alzheimer's disease psychosis.
Why it matters — ACAD watchers would follow this because the announced commercial expansion and upcoming Alzheimer's disease psychosis data for remlifanserin could shape expectations for the company's product reach and pipeline developments.
A Zacks Investment Research article compares the year-to-date performance of ACADIA Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) against their sector.
Why it matters — ACAD watchers would care because the piece assesses how ACAD is performing relative to both a peer and the broader medical sector.
Zacks reported that Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Why it matters — ACAD watchers would care because rising earnings estimates point to a possible continuation of the stock's recent upward momentum.
The 21 Wall Street analysts covering ACADIA Pharmaceuticals, Inc. have a median 12-month price target of $36, with estimates ranging from $17 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering ACADIA Pharmaceuticals, Inc., 16 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ACADIA Pharmaceuticals, Inc. 82 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, ACADIA Pharmaceuticals, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies +21.4% from the last close, and Ticker Nerd's factor model ranks ACADIA Pharmaceuticals, Inc. 82 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ACADIA Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACAD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $49 over the next 12 months.
ACADIA Pharmaceuticals, Inc. returned +15.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological disorders and rare diseases.
The most recent item we track (Zacks Investment Research, 24 Aug 2026): "Acadia Gets European Commission Nod for Daybu in Rett Syndrome". The European Commission approved Acadia Pharmaceuticals' Daybu, marking the first and only treatment approved in the EU for Rett syndrome. The approval expands Acadia's geographical reach for this therapy.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological disorders and rare diseases. The company’s primary purpose is to address conditions with significant unmet medical needs, particularly in central nervous system indications. Acadia’s commercial portfolio includes FDA-approved therapies for Parkinson’s disease psychosis and Rett syndrome, targeting patients who often have limited treatment options. Beyond its marketed products, Acadia is actively engaged in clinical development programs in areas such as Alzheimer’s disease psychosis and Lewy body dementia psychosis, as well as additional early-stage programs in other underserved neurological conditions. Headquartered in San Diego, California, Acadia serves healthcare providers, patients, and caregivers through a combination of proprietary research, regulatory expertise, and specialized commercial capabilities. The company plays a notable role in the biopharmaceutical market segment focused on neuroscience and orphan diseases, contributing differentiated therapies to a highly specialized treatment landscape.
CEO Ms. Catherine E. Owen Adams · 796 employees · United States · https://www.acadia.com
